Moleculin Biotech (Moleculin Biotech) Additional Paid-In Capital : $157.65 Mil(As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Moleculin Biotech Additional Paid-In Capital?

Moleculin Biotech's quarterly additional paid-in capital increased from Jun. 2023 ($155.96 Mil) to Sep. 2023 ($156.45 Mil) and increased from Sep. 2023 ($156.45 Mil) to Dec. 2023 ($157.65 Mil).

Moleculin Biotech's annual additional paid-in capital increased from Dec. 2021 ($151.73 Mil) to Dec. 2022 ($153.99 Mil) and increased from Dec. 2022 ($153.99 Mil) to Dec. 2023 ($157.65 Mil).

Moleculin Biotech Additional Paid-In Capital Historical Data

The historical data trend for Moleculin Biotech's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moleculin Biotech Additional Paid-In Capital Chart

Moleculin Biotech Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

55.06

74.67

151.73

153.99

157.65

Moleculin Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															153.99	155.40	155.96	156.45	157.65

Moleculin Biotech Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Moleculin Biotech Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Moleculin Biotech's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Moleculin Biotech (Moleculin Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moleculin Biotech Inc (NAS:MBRX) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

MOLA:Germany

Address

5300 Memorial Drive, Suite 950, Houston, TX, USA, 77007

Website

https://www.moleculin.com

Moleculin Biotech Inc is a clinical-stage pharmaceutical company with a focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next-generation anthracycline; Immune/Transcription Modulators, of which WP1066 is a member; and Metabolism/Glycosylation Inhibitors, of which WP1122 is a member.

Executives

Jonathan P. Foster	officer: Exec. Vice President and CFO	2450 SOUTH SHORE BLVD., SUITE 402, LEAGUE CITY TX 77573
Walter V Klemp	director, 10 percent owner, officer: Chairman and Acting CEO	1415 WEST LOOP NORTH, HOUSTON TX 77055
Robert E. George	director	2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
Joy Yan	director	10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Elizabeth Cermak	director	1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Waldemar Priebe	10 percent owner	2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
John M Climaco	director	PO BOX 326, PARK CITY UT 84060
Jacqueline Northcut	director	2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
Donald H Picker	10 percent owner, officer: President and COO
Michael D Cannon	director	C/O SICOR INC, 19 HUGHES, IRVINE CA 92618-1902
Louis Jr Ploth	officer: Chief Financial Officer	2408 TIMBERLOCH PLACE STE B1, WOODLANDS TX 77380